Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 79,266 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Active, not recruiting Phase 2 Interventional

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
CAL02, Placebo
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Enhancing Adaptations to Exercise

NCT03350906
View directory record Official record
Conditions
Inflammation
Interventions
n3-PUFA, Placebo, Biopsy, Body Composition Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 2 Interventional

VoIP Delivered Behavior Therapy for Tourette Syndrome

NCT02247206
View directory record Official record
Conditions
Tourette Syndrome, Chronic Tic Disorder
Interventions
Behavior Therapy for Tics (CBIT)
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Nov 2, 2026, 10:23 AM EST
Completed No phase listed Observational Accepts healthy volunteers

SPECT/CT Imaging of Skeletal Muscle Perfusion

NCT02791204
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetes Mellitus
Interventions
SPECT/CT imaging following revascularization procedures, SPECT/CT imaging
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

NCT02216084
View directory record Official record
Conditions
Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
Recombinant ADAMTS13
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Dublin, Ohio • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional

A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.

NCT00000833
View directory record Official record
Conditions
HIV Infections
Interventions
Ribavirin, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 2, 2026, 10:23 AM EST
Terminated Phase 3 Interventional Results available

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

NCT03445533
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tilsotolimod with Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 2, 2026, 10:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Dietary Guidelines 3 Diets Study

NCT04981847
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dietary Intervention Meetings
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Buffered Local Anesthetic

NCT05757648
View directory record Official record
Conditions
Dental Pain
Interventions
Non-buffered Anesthetic, Buffered Anesthetic, Onset
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 6 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional

Safety and Tolerability of Rituximab in Neuromyelitis Optica

NCT00501748
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 86 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Francisco, California • Columbia University Medical Center 710 West 168th Street,, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 3 Interventional

Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)

NCT00070655
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
SR34006 (idraparinux sodium) Injection, vitamin K antagonist (warfarin or acenocoumarol) tablets
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Nov 2, 2026, 10:23 AM EST
Recruiting Phase 1Phase 2 Interventional

SPEARHEAD-3 Pediatric Study

NCT05642455
View directory record Official record
Conditions
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
Interventions
Afamitresgene autoleucel
Genetic
Lead sponsor
USWM CT, LLC
Industry
Eligibility
2 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
10
States / cities
Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 2, 2026, 10:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)

NCT04332926
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
Tobacco product administration and assessment, own brand cigarettes, Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

NCT01539655
View directory record Official record
Conditions
Medullary Thyroid Cancer
Interventions
vandetanib, omeprazole, ranitidine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

NCT03524326
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Lenvatinib Pill, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Nov 2, 2026, 10:23 AM EST
Completed Not applicable Interventional

Durham Housing Authority (DHA) Community Health Advisor (CHA) Smoking Cessation Project

NCT04114526
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Replacement Therapy
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Nov 2, 2026, 10:23 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Immediate and 24-hour Effects of Body Tempering Versus Foam Rolling on Lower Extremity Muscular Power During the Vertical Jump and Standing Long Jump Tests

NCT06646926
View directory record Official record
Conditions
Lower Extremity Muscular Power Performance Output
Interventions
Body tempering, Foam rolling self-myofascial release
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 2 Interventional Results available

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

NCT04433585
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
La Jolla, California • Palm Desert, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

NCT01749085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04449913, ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

NCT00003143
View directory record Official record
Conditions
Lymphoma
Interventions
Amifostine, DHAP
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Social Network AOD Intervention for Homeless Youth Transitioning to Housing

NCT04637815
View directory record Official record
Conditions
Substance Use
Interventions
Motivational Network Intervention, Usual Care
Behavioral · Other
Lead sponsor
RAND
Other
Eligibility
18 Years to 25 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 2 Interventional

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

NCT00570635
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms
Interventions
XL820
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Park Ridge, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Nov 2, 2026, 10:23 AM EST
Completed Phase 1Phase 2 Interventional

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

NCT00664625
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-791325, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Anaheim, California • Cypress, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Nov 2, 2026, 10:23 AM EST